<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Hypertrophic cardiomyopathy in adults: Supraventricular tachycardias including atrial fibrillation</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Hypertrophic cardiomyopathy in adults: Supraventricular tachycardias including atrial fibrillation</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Hypertrophic cardiomyopathy in adults: Supraventricular tachycardias including atrial fibrillation</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Martin S Maron, MD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Samuel Lévy, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">William J McKenna, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Todd F Dardas, MD, MS</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Feb 03, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Hypertrophic cardiomyopathy (HCM) is a genetically determined heart muscle disease caused by mutations in one of several sarcomere genes that encode components of the contractile apparatus. (See  <a class="medical medical_review" href="/z/d/html/4956.html" rel="external">"Hypertrophic cardiomyopathy: Gene mutations and clinical genetic testing"</a>.)</p><p>HCM is characterized by left ventricular hypertrophy (LVH) of various morphologies  (<a class="graphic graphic_figure graphicRef58156" href="/z/d/graphic/58156.html" rel="external">figure 1</a>) and is commonly associated with atrial arrhythmias.</p><p>The evaluation and management of supraventricular tachycardias, primarily atrial fibrillation (AF), in patients with HCM will be reviewed here.</p><p>Other aspects of the clinical manifestations, diagnosis, and management of HCM in adults are discussed separately:</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/4916.html" rel="external">"Hypertrophic cardiomyopathy: Natural history and prognosis"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/4948.html" rel="external">"Hypertrophic cardiomyopathy: Clinical manifestations, diagnosis, and evaluation"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/4920.html" rel="external">"Hypertrophic cardiomyopathy: Management of patients with outflow tract obstruction"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/4950.html" rel="external">"Hypertrophic cardiomyopathy: Management of patients without outflow tract obstruction"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/4956.html" rel="external">"Hypertrophic cardiomyopathy: Gene mutations and clinical genetic testing"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/119625.html" rel="external">"Hypertrophic cardiomyopathy: Management of ventricular arrhythmias and sudden cardiac death risk"</a> and  <a class="medical medical_review" href="/z/d/html/4952.html" rel="external">"Hypertrophic cardiomyopathy: Risk stratification for sudden cardiac death"</a>.)</p><p></p><p class="headingAnchor" id="H266008303"><span class="h1">EPIDEMIOLOGY</span><span class="headingEndMark"> — </span>In patients with HCM, the prevalence of AF appears to be four- to sixfold higher than similarly aged patients in the general population, with an incidence in the range of 2 to 5 percent per year [<a href="#rid1">1-3</a>]. AF is rare in young patients with HCM who are less than 30 years of age. AF is paroxysmal in approximately two-thirds of patients and persistent or permanent in the remaining one-third:</p><p class="bulletIndent1"><span class="glyph">●</span>In a cohort of 4591 patients from the Sarcomeric Human Cardiomyopathy Registry (SHaRe) who were followed for a mean of 5.4 years, 20 percent developed AF at some point (no data were presented to determine paroxysmal versus permanent AF or burden of AF) [<a href="#rid4">4</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a cohort of 1558 consecutive patients with HCM who were followed at a referral center for an average of 4.8 years, AF occurred in 304 patients (20 percent), with 74 percent being paroxysmal AF and 26 percent developing permanent AF [<a href="#rid5">5</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a case-control study of 104 patients with HCM (52 case patients with HCM and AF at some point during follow-up, 52 controls with HCM and normal sinus rhythm) diagnosed between 1960 and 1985, AF was present in approximately 5 percent of patients at the time of diagnosis of HCM and developed in an additional 10 percent during the five years following diagnosis [<a href="#rid1">1</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a retrospective study of 75 patients with HCM with a dual-chamber implantable cardioverter-defibrillator (ICD) but no known history of AF, 21 patients (28 percent) developed AF over an average follow-up of five years [<a href="#rid3">3</a>]. Eighteen of the 21 patients developed asymptomatic AF episodes (ie, clinically silent), most of which lasted less than one hour; however, 13 of the 18 patients with clinically silent AF had more than one episode, and 8 of the 18 ultimately developed symptoms attributed to AF. Nonfatal embolic stroke occurred in 1 patient associated with asymptomatic AF and without other risk factors.</p><p></p><p class="headingAnchor" id="H266008473"><span class="h1">PATHOPHYSIOLOGY</span><span class="headingEndMark"> — </span>HCM is associated with a thick and noncompliant LV resulting in some degree of diastolic dysfunction in nearly all patients. Thus, patients with HCM are thought to be particularly dependent on the contribution of atrial systole to provide optimal LV filling and cardiac output. Diastolic dysfunction significantly impacts affected patients’ tolerance of AF and other atrial tachyarrhythmias. AF, with loss of atrial kick and associated rapid ventricular rates results in reduced diastolic LV filling time and LV filling, which contributes to increased heart failure symptoms. (See  <a class="medical medical_review" href="/z/d/html/3504.html" rel="external">"Heart failure with preserved ejection fraction: Clinical manifestations and diagnosis"</a> and  <a class="medical medical_review" href="/z/d/html/1041.html" rel="external">"Hemodynamic consequences of atrial fibrillation and cardioversion to sinus rhythm", section on 'Adverse hemodynamics in AF'</a>.)</p><p>Thus, diastolic dysfunction has a significant impact on a patient's ability to tolerate AF and other atrial tachyarrhythmias. (See  <a class="medical medical_review" href="/z/d/html/1041.html" rel="external">"Hemodynamic consequences of atrial fibrillation and cardioversion to sinus rhythm"</a>.)</p><p class="headingAnchor" id="H3"><span class="h1">PREDISPOSING FACTORS</span><span class="headingEndMark"> — </span>Several factors appear to be associated with risk for development of AF in patients with HCM, including [<a href="#rid2">2,6,7</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Increased left atrial diameter (eg, left atrial dimension &gt;45 mm) and volume</p><p class="bulletIndent1"><span class="glyph">●</span>Increasing age</p><p class="bulletIndent1"><span class="glyph">●</span>Left atrial dysfunction</p><p class="bulletIndent1"><span class="glyph">●</span>Severe and diffuse hypertrophy</p><p class="bulletIndent1"><span class="glyph">●</span>LV ejection fraction (LVEF), particularly when LVEF &lt;50 percent (end-stage HCM)</p><p></p><p>In contrast to these risk factors, the presence or severity of an LV outflow tract gradient does not appear to be associated with an increased incidence of AF [<a href="#rid8">8</a>].</p><p>There are limited data on atrial pathology in HCM, but some studies have shown extensive atrial fibrosis similar to that seen in patients with long-standing HF [<a href="#rid7">7</a>]. Myocyte disarray, present in the ventricular myocardium, has not been reported in the atria, and the expression of sarcomeric protein mutations in atrial tissue has not been studied.</p><p class="headingAnchor" id="H4"><span class="h1">CLINICAL MANIFESTATIONS</span><span class="headingEndMark"> — </span>While AF is often poorly tolerated in HCM and may be associated with significant symptoms and clinical deterioration, its impact of morbidity and mortality can be significantly mitigated with modern AF management [<a href="#rid1">1,2,5,9</a>]. While most patients with HCM who develop AF have prominent symptoms, not all patients are symptomatic. The clinical manifestations of AF in patients with HCM can be divided into acute symptoms and long-term consequences.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Acute presentation</strong> – For many patients with HCM, acute symptoms associated with AF are similar to symptoms of AF in patients without HCM such as palpitations, dyspnea, and chest pain. However, some patients with HCM and AF, especially those with LV outflow tract (LVOT) obstruction or severe diastolic dysfunction, develop symptomatic hypotension with lightheadedness, presyncope, or syncope. These symptoms are caused by decreased LV diastolic filling time during the tachycardia, which may also provoke or worsen an LVOT gradient. As an example, in a series of 52 patients with HCM who developed AF, the acute onset of AF was associated with worsening of functional class in 89 percent of patients [<a href="#rid1">1</a>]. With reversion to sinus rhythm or, to a lesser extent, with control of the ventricular rate, nearly all patients returned to their baseline functional class.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Long-term sequelae</strong> – The long-term studies of patients with HCM of both paroxysmal and persistent/permanent AF have been most strongly linked to an increase in limiting symptoms and an increase in risk of thromboembolic stroke, with less evidence linking AF to increasing heart failure-related death [<a href="#rid1">1,2,10,11</a>]. Unlike ventricular arrhythmias, AF and other atrial tachyarrhythmias are generally not associated with an increased risk of sudden cardiac death, though there are case reports in which AF with a rapid ventricular response has degenerated into ventricular tachycardia and ventricular fibrillation [<a href="#rid9">9,12,13</a>]. (See <a class="local">'Prognosis'</a> below.)</p><p></p><p>Conflicting data on the impact of AF on stroke and functional status in patients with HCM have been reported, which can be largely attributed to the application of contemporary therapies to treat AF, including advancement in catheter ablation techniques as well as surgical intervention with Cox-Maze and increasing recognition for low burden of AF to recommend anticoagulation for stroke prophylaxis:</p><p class="bulletIndent1"><span class="glyph">●</span>In a cohort of 480 patients, 22 percent of whom had paroxysmal or chronic AF, stroke risk was markedly increased in the patients with AF compared with those in sinus rhythm (21 percent for patients with AF versus 3 percent without AF; ) [<a href="#rid2">2</a>]. Additionally, the development of AF was associated with an increased risk of severe functional limitation (odds ratio 2.8 for developing NYHA class III/IV symptoms). The risk of stroke and deterioration of functional status was highest in patients with LVOT obstruction.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a cohort of 1558 patients, among whom 304 patients (20 percent) developed AF over a mean follow-up of 4.8 years, only 18 patients with AF (6 percent) experienced an embolic event, with only two deaths directly attributable to the embolic event (annual mortality of 0.1 percent due to thromboembolism) and no evidence to support the assertion that AF leads to long-term deterioration in functional status, including risk for progressive heart failure [<a href="#rid5">5</a>]. The risk of stroke was significantly higher among patients with AF not on long-term antithrombotic therapy (14 versus 2 percent).</p><p></p><p class="headingAnchor" id="H266008796"><span class="h1">DIAGNOSIS</span><span class="headingEndMark"> — </span>The diagnosis of AF is usually suspected in a patient with palpitations, dyspnea, or chest pain with an irregularly irregular pulse present on physical examination. However, not all patients with AF are symptomatic, but AF should be suspected in an asymptomatic patient with an irregularly irregular pulse on physical examination. In these situations, an electrocardiogram (ECG) should be promptly performed to verify the diagnosis.</p><p>Since left atrial (LA) size is a strong independent predictor of future AF, European guidelines recommend that all patients with HCM and LA diameter ≥45 mm undergo 48-hour ECG monitoring every 6 to 12 months to detect episodes of "silent" AF [<a href="#rid14">14</a>]. This recommendation is based on expert opinion with no published data on the efficacy of screening for AF with ECG monitoring. (See  <a class="medical medical_review" href="/z/d/html/1022.html" rel="external">"Atrial fibrillation: Overview and management of new-onset atrial fibrillation", section on 'Electrocardiogram'</a>.)</p><p>Patients with intermittent symptoms suggestive of paroxysmal AF may not be in AF at the time of the examination and initial ECG. In such patients, ambulatory monitoring for up to four weeks can aid in making the diagnosis. (See  <a class="medical medical_review" href="/z/d/html/1022.html" rel="external">"Atrial fibrillation: Overview and management of new-onset atrial fibrillation", section on 'Additional cardiac testing'</a> and  <a class="medical medical_review" href="/z/d/html/958.html" rel="external">"Ambulatory ECG monitoring"</a>.)</p><p class="headingAnchor" id="H8"><span class="h1">TREATMENT</span></p><p class="headingAnchor" id="H2121643698"><span class="h2">Atrial fibrillation</span><span class="headingEndMark"> — </span>In general, the therapeutic options for AF in patients with HCM are similar to those for patients without HCM  (<a class="graphic graphic_algorithm graphicRef119349" href="/z/d/graphic/119349.html" rel="external">algorithm 1</a>), with some caveats [<a href="#rid15">15,16</a>]. Since patients with HCM are frequently less tolerant of AF than patients without HCM, we favor a more aggressive approach to the maintenance of sinus rhythm in patients with HCM than in other settings. In addition, patients with HCM and AF are at an increased risk of thromboembolic events, including stroke, and the threshold to introduce anticoagulation should generally be low [<a href="#rid15">15,16</a>]. (See  <a class="medical medical_review" href="/z/d/html/1022.html" rel="external">"Atrial fibrillation: Overview and management of new-onset atrial fibrillation"</a>.)</p><p class="headingAnchor" id="H266009228"><span class="h3">Initial management</span><span class="headingEndMark"> — </span>The initial management of AF in patients with HCM is similar to that for any patient with AF [<a href="#rid16">16-19</a>].</p><p class="bulletIndent1"><span class="glyph">●</span>In patients who are asymptomatic or have only mild to moderate symptoms, initial therapy includes slowing the ventricular rate and concurrent initiation of anticoagulation therapy  (<a class="graphic graphic_algorithm graphicRef119349" href="/z/d/graphic/119349.html" rel="external">algorithm 1</a>). Beta blockers and nondihydropyridine calcium channel blockers (ie, <a class="drug drug_general" data-topicid="10043" href="/z/d/drug information/10043.html" rel="external">verapamil</a> and <a class="drug drug_general" data-topicid="9365" href="/z/d/drug information/9365.html" rel="external">diltiazem</a>) are preferred as first-line agents in most patients, and intravenous preparations are preferred to oral preparations when rapid control of rate is necessary. <a class="drug drug_general" data-topicid="9360" href="/z/d/drug information/9360.html" rel="external">Digoxin</a> should be avoided as a rate control agent in patients with HCM. (See <a class="local">'Rate control'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In patients with severe symptoms or who are hemodynamically unstable related to AF, urgent cardioversion should be performed.</p><p></p><p>The management of new-onset AF is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/1022.html" rel="external">"Atrial fibrillation: Overview and management of new-onset atrial fibrillation"</a>.) </p><p class="headingAnchor" id="H266009278"><span class="h3">Long-term management</span></p><p class="headingAnchor" id="H9"><span class="h4">Rhythm control</span><span class="headingEndMark"> — </span>In the majority of patients with HCM, AF is not well tolerated, often producing severe, limiting symptoms. A rate control strategy is a reasonable first option for all patients. However, given how symptomatic many patients with HCM are when they develop AF, and the low efficacy in controlling these symptoms with AV nodal blocking agents, greater weight should be given to pursuing an early rhythm control strategy. Notably, in patients with HCM who have <strong>asymptomatic</strong> paroxysmal or chronic AF, there are no clinical trials addressing the benefits of a rate versus rhythm control strategy. In this clinical scenario, expert opinion has generally supported rate control for AF in patients with HCM who are asymptomatic. (See <a class="local">'Rate control'</a> below.)</p><p>Rhythm control in patients with HCM and AF can be accomplished with either chemical or electrical cardioversion to restore sinus rhythm and antiarrhythmic drugs to suppress recurrences of AF, with catheter or surgical ablation in special circumstances  (<a class="graphic graphic_algorithm graphicRef119349" href="/z/d/graphic/119349.html" rel="external">algorithm 1</a>). The 2014 American Heart Association/American College of Cardiology/Heart Rhythm Society (AHA/ACC/HRS) AF guidelines and the 2014 European Society of Cardiology (ESC) HCM guidelines, as well as the 2016 ESC AF guidelines and the 2020 AHA/ACC HCM guidelines, concluded that the weight of evidence or opinion was in favor of the usefulness of antiarrhythmic drugs to prevent recurrent AF, although there are no randomized controlled trials evaluating the efficacy of either antiarrhythmic drug therapy or catheter ablation for preventing long-term recurrence of AF in patients with HCM [<a href="#rid17">17,19,20</a>].</p><p>There are few data to support the selection of a particular antiarrhythmic agent for maintenance of sinus rhythm in patients with HCM [<a href="#rid17">17,19</a>]. While data are limited, for maintenance of sinus rhythm in most patients with HCM and AF, our experts generally use <a class="drug drug_general" data-topicid="9941" href="/z/d/drug information/9941.html" rel="external">sotalol</a> as first-line antiarrhythmic therapy. Sotalol should be started on an inpatient basis, regardless of whether the patient has an ICD or not, monitoring over several doses for clinically significant prolongation of the QT interval or proarrhythmia. As an alternative initial therapeutic option, <a class="drug drug_general" data-topicid="9378" href="/z/d/drug information/9378.html" rel="external">disopyramide</a> may be used but is considered less effective in suppressing AF than sotalol, and due to the possibility that disopyramide may accelerate atrioventricular (AV) conduction, it must be given in combination with an AV nodal blocking agent, such as a beta blocker or a nondihydropyridine calcium channel blocker [<a href="#rid17">17,21</a>]. In addition, the use of disopyramide should be confined to patients with left ventricular outflow tract obstruction (where it has been demonstrated to be safe), as its use in nonobstructive patients can increase filling pressures and may cause heart failure symptoms. One exception to the use of sotalol (or disopyramide) in suppressing AF would be to consider <a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">amiodarone</a> initially in those patients with HCM in whom long-term use of the drug is unlikely based on the patient's advanced age or if a short-term duration of antiarrhythmic therapy is planned. If sotalol is not efficacious or not well tolerated, <a class="drug drug_general" data-topicid="8904" href="/z/d/drug information/8904.html" rel="external">dofetilide</a> could be considered, but limited data exist on its safety in HCM [<a href="#rid22">22</a>], and therefore in most circumstances its use should be confined to those patients with ICDs. (See  <a class="medical medical_review" href="/z/d/html/1035.html" rel="external">"Antiarrhythmic drugs to maintain sinus rhythm in patients with atrial fibrillation: Recommendations"</a>.)</p><p>In selected cases, for patients with nonobstructive HCM who have recurrent AF resulting in worsening symptoms and functional status, catheter-based radiofrequency ablation may be most appropriate, while isolated maze could be considered as an alternative option. Catheter ablation of AF with a technique of pulmonary vein isolation appears to be safe and effective for patients with HCM, with outcomes that may be similar to patients with other forms of structural heart disease who have AF [<a href="#rid23">23-30</a>]. As examples:</p><p class="bulletIndent1"><span class="glyph">●</span>Among a single-center cohort of 79 patients with HCM and AF refractory to antiarrhythmic medications who underwent catheter ablation, 71 percent of patients had no documented recurrent AF over an average of 35 months following the ablation [<a href="#rid26">26</a>]. However, in a different cohort of 49 patients who underwent 72 catheter ablation procedures, freedom from AF at one-year post-ablation was only 44 percent, dropping to 32 percent at three-years post-ablation [<a href="#rid5">5</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a systematic review and meta-analysis that included 531 patients from 15 nonrandomized trials, with significant heterogeneity among the various patient cohorts, freedom from AF following a single procedure (at the latest available follow-up which ranged between 11 and 54 months) averaged 46 percent, which increased to 66 percent following repeat ablation procedures [<a href="#rid28">28</a>]. Similar results were reported in a separate systematic review and meta-analysis that included 139 patients from six studies, in which the freedom from AF was 39 percent after a single procedure [<a href="#rid29">29</a>].</p><p></p><p>Catheter ablation of AF is discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/949.html" rel="external">"Atrial fibrillation: Catheter ablation"</a>.)</p><p>Similarly, in patients with obstructive HCM who are undergoing surgical myectomy and who have symptomatic AF, an adjunctive surgical Cox-Maze procedure for AF ablation should be considered as a possible therapeutic option that has been shown to be safe and effective only in case reports and small series of patients [<a href="#rid5">5,14,31-33</a>]. Among a single-center cohort of 62 patients who underwent surgical Cox-Maze IV procedure at the time of septal myectomy between 2004 and 2015, freedom from AF at one-, three-, and five-year post-procedure was 85, 69, and 64 percent, respectively [<a href="#rid33">33</a>]. (See  <a class="medical medical_review" href="/z/d/html/1046.html" rel="external">"Atrial fibrillation: Surgical ablation"</a>.)</p><p class="headingAnchor" id="H10"><span class="h4">Rate control</span><span class="headingEndMark"> — </span>Because of the lack of controlled data demonstrating a benefit from maintaining sinus rhythm in patients with HCM and AF, and also because of the potential side effects associated with antiarrhythmic drugs, some patients and clinicians will select a rate control strategy, particularly in asymptomatic or minimally symptomatic patients  (<a class="graphic graphic_algorithm graphicRef119349" href="/z/d/graphic/119349.html" rel="external">algorithm 1</a>). For patients in whom a rate control strategy is selected, we recommend the use of beta blockers, calcium channel blockers, or the two drugs in combination, rather than <a class="drug drug_general" data-topicid="9360" href="/z/d/drug information/9360.html" rel="external">digoxin</a>.</p><p>For the majority of patients with HCM, onset of AF results in an acute development of limiting symptoms (or worsening of existing symptoms), which often substantially impacts the patient's quality of life. For this reason, the goal is often maintenance of sinus rhythm, as restoration of atrial contribution to stroke volume is so important. However, in the minority of patients with HCM and AF who are asymptomatic, a rate control strategy can be considered initially or in those patients who have failed efforts at rhythm control and who are not candidates for an ablation procedure.</p><p>Ventricular rate control can be achieved with pharmacologic or nonpharmacologic means. Beta blockers, nondihydropyridine calcium channel blockers (ie, <a class="drug drug_general" data-topicid="10043" href="/z/d/drug information/10043.html" rel="external">verapamil</a> and <a class="drug drug_general" data-topicid="9365" href="/z/d/drug information/9365.html" rel="external">diltiazem</a>), or the two drugs in combination are usually adequate to control the ventricular rate [<a href="#rid14">14,17,18,20</a>]. Although there are no data on the use and safety of <a class="drug drug_general" data-topicid="9360" href="/z/d/drug information/9360.html" rel="external">digoxin</a> as a rate control agent in HCM, based on expert opinion and standard practice, digoxin should not be used in patients with AF and HCM, since it can increase inotropy, which could exacerbate heart failure symptoms in the majority of patients with HCM who have preserved systolic function. (See  <a class="medical medical_review" href="/z/d/html/938.html" rel="external">"Control of ventricular rate in patients with atrial fibrillation who do not have heart failure: Pharmacologic therapy"</a>.)</p><p>When the ventricular rate cannot be controlled with medications and the patient is not considered a candidate for catheter or surgical ablation of AF, AV nodal ablation with pacemaker implantation will provide definitive control of the ventricular rate [<a href="#rid14">14</a>].</p><p class="headingAnchor" id="H1971940164"><span class="h4">Anticoagulation</span><span class="headingEndMark"> — </span>Limited evidence is available to guide anticoagulant therapy in patients with HCM and AF. Patients with HCM and AF are at significant risk of thromboembolism, although risk factors for thromboembolism have not been well defined [<a href="#rid2">2,14,17,20</a>]. Since patients with HCM were not included in most clinical trials of thromboprophylaxis in AF, the CHA<sub>2</sub>DS<sub>2</sub>-VASc score cannot be applied to patients with this condition to determine the risk of thromboembolism.</p><p class="headingAnchor" id="H11"><span class="h5">For symptomatic AF</span><span class="headingEndMark"> — </span>For patients with HCM and symptomatic AF, we recommend chronic oral anticoagulation  (<a class="graphic graphic_algorithm graphicRef119349" href="/z/d/graphic/119349.html" rel="external">algorithm 1</a>). This recommendation applies for symptomatic AF, regardless of the duration of episodes of AF. Either a direct oral anticoagulant (DOAC; eg, <a class="drug drug_general" data-topicid="8926" href="/z/d/drug information/8926.html" rel="external">dabigatran</a>, <a class="drug drug_general" data-topicid="9498" href="/z/d/drug information/9498.html" rel="external">rivaroxaban</a>, <a class="drug drug_general" data-topicid="85642" href="/z/d/drug information/85642.html" rel="external">apixaban</a>, <a class="drug drug_general" data-topicid="99275" href="/z/d/drug information/99275.html" rel="external">edoxaban</a>) or <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">warfarin</a> (with a target international normalized ratio [INR] of 2 to 3) can be chosen as the initial thrombotic regimen in patients with HCM and AF [<a href="#rid15">15,19</a>].</p><p>Support for this approach to comes from a study of 304 HCM patients with AF followed for a mean of 4.8 years [<a href="#rid5">5</a>]. Embolic events occurred in only 2 percent of patients taking anticoagulation therapy compared with 14 percent among HCM patients with AF not taking anticoagulation. Only two deaths were directly attributable to an embolic event (annual mortality of 0.1 percent due to thromboembolism).</p><p>Whether a threshold amount of AF exists to recommend anticoagulation is uncertain, and, since patients with HCM are not included in most clinical trials of thromboprophylaxis in AF, the CHA<sub>2</sub>DS<sub>2</sub>-VASc score cannot be applied to patients with this disease to determine the benefit of anticoagulation.</p><p>Several studies have documented the increased risk of thromboembolic events in patients with HCM and AF [<a href="#rid2">2,17,19,34,35</a>]. In a series of 480 patients with HCM, of whom 22 percent had paroxysmal or chronic AF, stroke risk was markedly increased in the patients with AF compared with those in sinus rhythm (odds ratio 17.7) [<a href="#rid2">2</a>]. The elevated risk of thromboembolic events includes patients treated with rhythm control who appear to be in normal sinus rhythm, given the risk of recurrent AF with minimal or no symptoms. (See  <a class="medical medical_review" href="/z/d/html/1031.html" rel="external">"Atrial fibrillation in adults: Use of oral anticoagulants"</a>.)</p><p>Specific antithrombotic regimens in patients with HCM have not been studied in randomized trials. Both <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">warfarin</a> therapy (with a target INR of 2 to 3) and the DOACs (eg, <a class="drug drug_general" data-topicid="8926" href="/z/d/drug information/8926.html" rel="external">dabigatran</a>, <a class="drug drug_general" data-topicid="9498" href="/z/d/drug information/9498.html" rel="external">rivaroxaban</a>, <a class="drug drug_general" data-topicid="85642" href="/z/d/drug information/85642.html" rel="external">apixaban</a>, <a class="drug drug_general" data-topicid="99275" href="/z/d/drug information/99275.html" rel="external">edoxaban</a>) have been shown to be efficacious in other populations without HCM. Data from observational studies suggest that both warfarin and DOACs are safe and effective in reducing thromboembolic risk.</p><p class="bulletIndent1"><span class="glyph">●</span>Among 2397 patients with HCM and AF treated with anticoagulation who were enrolled in a nationwide Korean database between 2013 and 2016 and followed for 1.6 years, rates of embolic ischemic stroke and bleeding complications were significantly lower among patients treated with a DOAC compared with <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">warfarin</a> [<a href="#rid36">36</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Among 2198 patients with HCM and AF treated with anticoagulation who were identified from a United States commercial insurance database between 2010 and 2015, rates of embolic ischemic stroke and bleeding were similar between <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">warfarin</a> and DOACs over short-term follow-up [<a href="#rid37">37</a>].</p><p></p><p>Either approach can be considered as the initial antithrombotic regimen in patients with HCM and AF [<a href="#rid14">14,17,20</a>]. (See  <a class="medical medical_review" href="/z/d/html/1370.html" rel="external">"Direct oral anticoagulants (DOACs) and parenteral direct-acting anticoagulants: Dosing and adverse effects"</a>.)</p><p class="headingAnchor" id="H3037758262"><span class="h5">For asymptomatic AF</span><span class="headingEndMark"> — </span>In patients with HCM, asymptomatic or subclinical AF can be detected by external monitoring or device downloads. There are limited data on the prevalence of subclinical AF in HCM.</p><p class="bulletIndent1"><span class="glyph">●</span>Among 30 patients with HCM, 14 were noted to have evidence of subclinical AF over a follow-up of 595 days [<a href="#rid38">38</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Among 114 patients with HCM followed for 2.8 years, subclinical AF detected by device download occurred at a rate of 4 percent per year [<a href="#rid39">39</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a retrospective study of patients with HCM with a dual-chamber ICD but no known history of AF, patients developed asymptomatic AF episodes (ie, clinically silent), most of which lasted less than one hour; however, 13 of the 18 patients with clinically silent AF had more than one episode [<a href="#rid3">3</a>].</p><p></p><p>There is debate regarding the burden of subclinical AF necessary to recommend DOACs for stroke prophylaxis. Extrapolating from non-HCM studies, episodes of subclinical AF &gt;24 hours were associated with increased stroke risk compared with shorter episodes [<a href="#rid40">40</a>]. For this reason, the 2020 AHA/ACC HCM guidelines recommend DOAC therapy for patients with HCM detected with subclinical AF &gt;24 hours duration [<a href="#rid19">19</a>]. For shorter episodes of &gt;5 minutes to 24 hours, it would also be reasonable to consider DOAC therapy while also taking into consideration important clinical variables, such as length and burden of AF episodes, and the strengths and limitations of long-term anticoagulation therapy, including bleeding risk, for an individual patient.</p><p class="headingAnchor" id="H1339964410"><span class="h2">Atrial flutter and other supraventricular tachycardias</span><span class="headingEndMark"> — </span>The approach to the management of atrial flutter in patients with HCM is similar to the approach in patients without HCM. Given the high success rates for radiofrequency ablation in eliminating atrial flutter, this should be considered early in patients with HCM. (See  <a class="medical medical_review" href="/z/d/html/1065.html" rel="external">"Atrial flutter: Maintenance of sinus rhythm", section on 'RF catheter ablation'</a>.)</p><p>Nonsustained supraventricular tachycardias (SVTs) are commonly found during ambulatory electrocardiographic monitoring in patients with HCM. The majority of these events are asymptomatic and self-limited. Up to 25 percent of patients with HCM will have such arrhythmias, but they rarely require therapy [<a href="#rid41">41</a>]. (See  <a class="medical medical_review" href="/z/d/html/943.html" rel="external">"Narrow QRS complex tachycardias: Clinical manifestations, diagnosis, and evaluation"</a> and  <a class="medical medical_review" href="/z/d/html/936.html" rel="external">"Overview of the acute management of tachyarrhythmias"</a>.)</p><p class="headingAnchor" id="H266008545"><span class="h1">PROGNOSIS</span><span class="headingEndMark"> — </span>In addition to the symptoms associated with AF and the risk of worsening heart failure and stroke, mortality is higher in adults with HCM who develop AF [<a href="#rid2">2,42,43</a>].</p><p class="bulletIndent1"><span class="glyph">●</span>In a single-center cohort of 3673 patients with HCM evaluated between 1975 and 2012, 650 patients (18 percent) had AF; patients with AF were older and more often symptomatic, and AF was associated with increased total mortality (adjusted hazard ratio 1.5, 95% CI 1.3-1.7) [<a href="#rid43">43</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a cohort of 202 Italian adults with HCM who were followed for up to 30 years (mean 10 years), the 57 patients (28 percent) with AF had a significantly higher mortality at 15 years (24 versus 3 percent in patients with HCM and no AF) [<a href="#rid42">42</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a cohort of 480 adults with HCM from the United States and Italy who were followed for an average of 9.1 years, intermittent or permanent AF significantly increased the rate of HCM-related death, primarily due to heart failure deaths and not sudden cardiac death [<a href="#rid2">2</a>]. The risk of death was associated with the presence of left ventricular outflow tract obstruction and AF onset before age 50 years.</p><p></p><p class="headingAnchor" id="H1187948377"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/112091.html" rel="external">"Society guideline links: Atrial fibrillation"</a> and  <a class="medical medical_society_guidelines" href="/z/d/html/115416.html" rel="external">"Society guideline links: Cardiomyopathy"</a>.)</p><p class="headingAnchor" id="H1394082"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topic (see  <a class="medical medical_basics" href="/z/d/html/15753.html" rel="external">"Patient education: Hypertrophic cardiomyopathy in adults (The Basics)"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Beyond the Basics topic (see  <a class="medical medical_patient" href="/z/d/html/3445.html" rel="external">"Patient education: Hypertrophic cardiomyopathy (Beyond the Basics)"</a>)</p><p></p><p class="headingAnchor" id="H15"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Epidemiology</strong> – In patients with hypertrophic cardiomyopathy (HCM), the prevalence of atrial fibrillation (AF) appears to be four- to sixfold higher than in similarly aged patients in the general population, with an incidence in the range of 2 percent per year. (See <a class="local">'Epidemiology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Risk factors</strong> – Several factors predispose to the development of AF in patients with HCM, including increased left atrial diameter and volume, left atrial dysfunction, increasing age, and left ventricular ejection fraction (LVEF), particularly when LVEF &lt;50 percent (end-stage HCM). In contrast to these risk factors, the presence or severity of an LV outflow tract (LVOT) gradient does not appear to be associated with an increased incidence of AF. (See <a class="local">'Predisposing factors'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical manifestations</strong> – While most patients with HCM who develop AF have fairly prominent symptoms, not all patients will be symptomatic. The acute symptoms associated with AF in patients with HCM, which may include palpitations, dyspnea, and chest pain, are similar to the symptoms of AF in patients without HCM. However, patients with HCM, especially those with an LVOT gradient, are also at risk for hypotension, lightheadedness, presyncope, and syncope. (See <a class="local">'Clinical manifestations'</a> above.)</p><p></p><p class="bulletIndent1">The long-term consequences of both paroxysmal and persistent/permanent AF in patients with HCM include an increase in limiting symptoms and risk of thromboembolic stroke, as well as decreased overall functional status. Unlike ventricular arrhythmias, however, AF is not clearly associated with an increased risk of sudden cardiac death. (See <a class="local">'Clinical manifestations'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnosis</strong> – The diagnosis of AF is usually suspected in a patient with palpitations, dyspnea, or chest pain with an irregularly irregular pulse present on physical examination and confirmed by obtaining an ECG. (See <a class="local">'Diagnosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Initial management</strong> – In patients who are asymptomatic or have only mild to moderate symptoms, the initial management of AF is similar to other patients with AF and includes slowing the ventricular rate and concurrent initiation of anticoagulation therapy  (<a class="graphic graphic_algorithm graphicRef119349" href="/z/d/graphic/119349.html" rel="external">algorithm 1</a>). (See <a class="local">'Initial management'</a> above and  <a class="medical medical_review" href="/z/d/html/1025.html" rel="external">"Atrial fibrillation: Cardioversion"</a> and  <a class="medical medical_review" href="/z/d/html/983.html" rel="external">"Cardioversion for specific arrhythmias"</a>.)</p><p></p><p class="bulletIndent1">In patients with severe symptoms or who are hemodynamically unstable related to AF, urgent cardioversion should be performed.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Long-term management</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Rhythm versus rate control</strong> –<strong> </strong>In symptomatic patients with HCM and paroxysmal or persistent AF, we suggest a rhythm control strategy (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). This can be accomplished with either chemical or electrical cardioversion to restore sinus rhythm and antiarrhythmic drugs to suppress recurrences of AF. Although various professional society guidelines have concluded that the available data were insufficient to recommend one antiarrhythmic drug over another, our experts generally use <a class="drug drug_general" data-topicid="9941" href="/z/d/drug information/9941.html" rel="external">sotalol</a> (rather than <a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">amiodarone</a> or <a class="drug drug_general" data-topicid="9378" href="/z/d/drug information/9378.html" rel="external">disopyramide</a>). In selected cases, catheter-based radiofrequency ablation or a surgical maze procedure may be appropriate. (See <a class="local">'Rhythm control'</a> above.)</p><p></p><p class="bulletIndent2">A rate control strategy is also reasonable. For patients in whom a rate control strategy is selected, we recommend the use of beta blockers, calcium channel blockers, or the two drugs in combination, rather than <a class="drug drug_general" data-topicid="9360" href="/z/d/drug information/9360.html" rel="external">digoxin</a> (<a class="grade" href="https:///uptodate/show/grade_2" rel="external">Grade 1B</a>). (See <a class="local">'Rate control'</a> above.)</p><p></p><p class="bulletIndent2">If rate control is not achieved with medications and catheter or surgical ablation is not an option, patients may undergo atrioventricular (AV) nodal ablation with placement of a permanent pacemaker for definitive rate control. (See <a class="local">'Rate control'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Anticoagulation</strong> – The CHA<sub>2</sub>DS<sub>2</sub>-VASc score has not been studied in patients with HCM and therefore cannot be applied to patients with AF and HCM to determine need for anticoagulation.</p><p></p><p class="bulletIndent2">For patients with HCM and clinical AF and subclinical AF &gt;24 hours duration, we recommend chronic oral anticoagulation (<a class="grade" href="https:///uptodate/show/grade_1" rel="external">Grade 1A</a>). Either <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">warfarin</a> (with a target international normalized ratio [INR] of 2 to 3) or one of the direct oral anticoagulants (DOACs; eg, <a class="drug drug_general" data-topicid="8926" href="/z/d/drug information/8926.html" rel="external">dabigatran</a>, <a class="drug drug_general" data-topicid="9498" href="/z/d/drug information/9498.html" rel="external">rivaroxaban</a>, <a class="drug drug_general" data-topicid="85642" href="/z/d/drug information/85642.html" rel="external">apixaban</a>) can be chosen as the initial thrombotic regimen in patients with HCM and AF. For patients with shorter episodes of subclinical AF, anticoagulation therapy may be reasonable. (See <a class="local">'Treatment'</a> above and  <a class="medical medical_review" href="/z/d/html/1031.html" rel="external">"Atrial fibrillation in adults: Use of oral anticoagulants"</a>.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Robinson K, Frenneaux MP, Stockins B, et al. Atrial fibrillation in hypertrophic cardiomyopathy: a longitudinal study. J Am Coll Cardiol 1990; 15:1279.</a></li><li><a class="nounderline abstract_t">Olivotto I, Cecchi F, Casey SA, et al. Impact of atrial fibrillation on the clinical course of hypertrophic cardiomyopathy. Circulation 2001; 104:2517.</a></li><li><a class="nounderline abstract_t">Rowin EJ, Orfanos A, Estes NA, et al. Occurrence and Natural History of Clinically Silent Episodes of Atrial Fibrillation in Hypertrophic Cardiomyopathy. Am J Cardiol 2017.</a></li><li><a class="nounderline abstract_t">Ho CY, Day SM, Ashley EA, et al. Genotype and Lifetime Burden of Disease in Hypertrophic Cardiomyopathy: Insights from the Sarcomeric Human Cardiomyopathy Registry (SHaRe). Circulation 2018; 138:1387.</a></li><li><a class="nounderline abstract_t">Rowin EJ, Hausvater A, Link MS, et al. Clinical Profile and Consequences of Atrial Fibrillation in Hypertrophic Cardiomyopathy. Circulation 2017; 136:2420.</a></li><li><a class="nounderline abstract_t">Tani T, Tanabe K, Ono M, et al. Left atrial volume and the risk of paroxysmal atrial fibrillation in patients with hypertrophic cardiomyopathy. J Am Soc Echocardiogr 2004; 17:644.</a></li><li><a class="nounderline abstract_t">Sivalokanathan S, Zghaib T, Greenland GV, et al. Hypertrophic Cardiomyopathy Patients With Paroxysmal Atrial Fibrillation Have a High Burden of Left Atrial Fibrosis by Cardiac Magnetic Resonance Imaging. JACC Clin Electrophysiol 2019; 5:364.</a></li><li><a class="nounderline abstract_t">Savage DD, Seides SF, Maron BJ, et al. Prevalence of arrhythmias during 24-hour electrocardiographic monitoring and exercise testing in patients with obstructive and nonobstructive hypertrophic cardiomyopathy. Circulation 1979; 59:866.</a></li><li><a class="nounderline abstract_t">Stafford WJ, Trohman RG, Bilsker M, et al. Cardiac arrest in an adolescent with atrial fibrillation and hypertrophic cardiomyopathy. J Am Coll Cardiol 1986; 7:701.</a></li><li><a class="nounderline abstract_t">Spirito P, Chiarella F, Carratino L, et al. Clinical course and prognosis of hypertrophic cardiomyopathy in an outpatient population. N Engl J Med 1989; 320:749.</a></li><li><a class="nounderline abstract_t">Higashikawa M, Nakamura Y, Yoshida M, Kinoshita M. Incidence of ischemic strokes in hypertrophic cardiomyopathy is markedly increased if complicated by atrial fibrillation. Jpn Circ J 1997; 61:673.</a></li><li><a class="nounderline abstract_t">Suzuki M, Hirayama T, Marumoto K, et al. Paroxysmal atrial fibrillation as a cause of potentially lethal ventricular arrhythmia with myocardial ischemia in hypertrophic cardiomyopathy--a case report. Angiology 1998; 49:653.</a></li><li><a class="nounderline abstract_t">Boriani G, Rapezzi C, Biffi M, et al. Atrial fibrillation precipitating sustained ventricular tachycardia in hypertrophic cardiomyopathy. J Cardiovasc Electrophysiol 2002; 13:954.</a></li><li><a class="nounderline abstract_t">Authors/Task Force members, Elliott PM, Anastasakis A, et al. 2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC). Eur Heart J 2014; 35:2733.</a></li><li><a class="nounderline abstract_t">MacIntyre C, Lakdawala NK. Management of Atrial Fibrillation in Hypertrophic Cardiomyopathy. Circulation 2016; 133:1901.</a></li><li><a class="nounderline abstract_t">Veselka J, Anavekar NS, Charron P. Hypertrophic obstructive cardiomyopathy. Lancet 2017; 389:1253.</a></li><li><a class="nounderline abstract_t">January CT, Wann LS, Alpert JS, et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society. Circulation 2014; 130:e199.</a></li><li><a class="nounderline abstract_t">Gersh BJ, Maron BJ, Bonow RO, et al. 2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2011; 124:e783.</a></li><li><a class="nounderline abstract_t">Ommen SR, Mital S, Burke MA, et al. 2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation 2020; 142:e558.</a></li><li><a class="nounderline abstract_t">Hindricks G, Potpara T, Dagres N, et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Eur Heart J 2021; 42:373.</a></li><li><a class="nounderline abstract_t">Spirito P, Seidman CE, McKenna WJ, Maron BJ. The management of hypertrophic cardiomyopathy. N Engl J Med 1997; 336:775.</a></li><li><a class="nounderline abstract_t">Moore JC, Trager L, Anzia LE, et al. Dofetilide for suppression of atrial fibrillation in hypertrophic cardiomyopathy: A case series and literature review. Pacing Clin Electrophysiol 2018; 41:396.</a></li><li><a class="nounderline abstract_t">Liu X, Ouyang F, Mavrakis H, et al. Complete pulmonary vein isolation guided by three-dimensional electroanatomical mapping for the treatment of paroxysmal atrial fibrillation in patients with hypertrophic obstructive cardiomyopathy. Europace 2005; 7:421.</a></li><li><a class="nounderline abstract_t">Kilicaslan F, Verma A, Saad E, et al. Efficacy of catheter ablation of atrial fibrillation in patients with hypertrophic obstructive cardiomyopathy. Heart Rhythm 2006; 3:275.</a></li><li><a class="nounderline abstract_t">Gaita F, Di Donna P, Olivotto I, et al. Usefulness and safety of transcatheter ablation of atrial fibrillation in patients with hypertrophic cardiomyopathy. Am J Cardiol 2007; 99:1575.</a></li><li><a class="nounderline abstract_t">Bassiouny M, Lindsay BD, Lever H, et al. Outcomes of nonpharmacologic treatment of atrial fibrillation in patients with hypertrophic cardiomyopathy. Heart Rhythm 2015; 12:1438.</a></li><li><a class="nounderline abstract_t">Santangeli P, Di Biase L, Themistoclakis S, et al. Catheter ablation of atrial fibrillation in hypertrophic cardiomyopathy: long-term outcomes and mechanisms of arrhythmia recurrence. Circ Arrhythm Electrophysiol 2013; 6:1089.</a></li><li><a class="nounderline abstract_t">Zhao DS, Shen Y, Zhang Q, et al. Outcomes of catheter ablation of atrial fibrillation in patients with hypertrophic cardiomyopathy: a systematic review and meta-analysis. Europace 2016; 18:508.</a></li><li><a class="nounderline abstract_t">Providencia R, Elliott P, Patel K, et al. Catheter ablation for atrial fibrillation in hypertrophic cardiomyopathy: a systematic review and meta-analysis. Heart 2016; 102:1533.</a></li><li><a class="nounderline abstract_t">Zheng S, Jiang W, Dai J, et al. Five-year outcomes after catheter ablation for atrial fibrillation in patients with hypertrophic cardiomyopathy. J Cardiovasc Electrophysiol 2020; 31:621.</a></li><li><a class="nounderline abstract_t">Chen MS, McCarthy PM, Lever HM, et al. Effectiveness of atrial fibrillation surgery in patients with hypertrophic cardiomyopathy. Am J Cardiol 2004; 93:373.</a></li><li><a class="nounderline abstract_t">Matsui Y, Fukada Y, Imai T, et al. Combined cox maze procedure, septal myectomy, and mitral valve replacement for severe hypertrophic obstructive cardiomyopathy complicated by chronic atrial fibrillation. Ann Thorac Cardiovasc Surg 2003; 9:323.</a></li><li><a class="nounderline abstract_t">Boll G, Rowin EJ, Maron BJ, et al. Efficacy of Combined Cox-Maze IV and Ventricular Septal Myectomy for Treatment of Atrial Fibrillation in Patients With Obstructive Hypertrophic Cardiomyopathy. Am J Cardiol 2020; 125:120.</a></li><li><a class="nounderline abstract_t">Darby AE, Dimarco JP. Management of atrial fibrillation in patients with structural heart disease. Circulation 2012; 125:945.</a></li><li><a class="nounderline abstract_t">Tsuda T, Hayashi K, Fujino N, et al. Effect of hypertrophic cardiomyopathy on the prediction of thromboembolism in patients with nonvalvular atrial fibrillation. Heart Rhythm 2019; 16:829.</a></li><li><a class="nounderline abstract_t">Lee HJ, Kim HK, Jung JH, et al. Novel Oral Anticoagulants for Primary Stroke Prevention in Hypertrophic Cardiomyopathy Patients With Atrial Fibrillation. Stroke 2019; 50:2582.</a></li><li><a class="nounderline abstract_t">Noseworthy PA, Yao X, Shah ND, Gersh BJ. Stroke and Bleeding Risks in NOAC- and Warfarin-Treated Patients With Hypertrophic Cardiomyopathy and Atrial Fibrillation. J Am Coll Cardiol 2016; 67:3020.</a></li><li><a class="nounderline abstract_t">Wilke I, Witzel K, Münch J, et al. High Incidence of De Novo and Subclinical Atrial Fibrillation in Patients With Hypertrophic Cardiomyopathy and Cardiac Rhythm Management Device. J Cardiovasc Electrophysiol 2016; 27:779.</a></li><li><a class="nounderline abstract_t">van Velzen HG, Theuns DA, Yap SC, et al. Incidence of Device-Detected Atrial Fibrillation and Long-Term Outcomes in Patients With Hypertrophic Cardiomyopathy. Am J Cardiol 2017; 119:100.</a></li><li><a class="nounderline abstract_t">Van Gelder IC, Healey JS, Crijns HJGM, et al. Duration of device-detected subclinical atrial fibrillation and occurrence of stroke in ASSERT. Eur Heart J 2017; 38:1339.</a></li><li><a class="nounderline abstract_t">McKenna WJ, England D, Doi YL, et al. Arrhythmia in hypertrophic cardiomyopathy. I: Influence on prognosis. Br Heart J 1981; 46:168.</a></li><li><a class="nounderline abstract_t">Cecchi F, Olivotto I, Montereggi A, et al. Hypertrophic cardiomyopathy in Tuscany: clinical course and outcome in an unselected regional population. J Am Coll Cardiol 1995; 26:1529.</a></li><li><a class="nounderline abstract_t">Siontis KC, Geske JB, Ong K, et al. Atrial fibrillation in hypertrophic cardiomyopathy: prevalence, clinical correlations, and mortality in a large high-risk population. J Am Heart Assoc 2014; 3:e001002.</a></li></ol></div><div id="topicVersionRevision">Topic 4926 Version 38.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2329232" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Atrial fibrillation in hypertrophic cardiomyopathy: a longitudinal study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11714644" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Impact of atrial fibrillation on the clinical course of hypertrophic cardiomyopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28395893" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Occurrence and Natural History of Clinically Silent Episodes of Atrial Fibrillation in Hypertrophic Cardiomyopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30297972" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Genotype and Lifetime Burden of Disease in Hypertrophic Cardiomyopathy: Insights from the Sarcomeric Human Cardiomyopathy Registry (SHaRe).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28916640" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Clinical Profile and Consequences of Atrial Fibrillation in Hypertrophic Cardiomyopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15163936" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Left atrial volume and the risk of paroxysmal atrial fibrillation in patients with hypertrophic cardiomyopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30898240" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Hypertrophic Cardiomyopathy Patients With Paroxysmal Atrial Fibrillation Have a High Burden of Left Atrial Fibrosis by Cardiac Magnetic Resonance Imaging.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/154981" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Prevalence of arrhythmias during 24-hour electrocardiographic monitoring and exercise testing in patients with obstructive and nonobstructive hypertrophic cardiomyopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3950248" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Cardiac arrest in an adolescent with atrial fibrillation and hypertrophic cardiomyopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2646539" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Clinical course and prognosis of hypertrophic cardiomyopathy in an outpatient population.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9276772" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Incidence of ischemic strokes in hypertrophic cardiomyopathy is markedly increased if complicated by atrial fibrillation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9717897" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Paroxysmal atrial fibrillation as a cause of potentially lethal ventricular arrhythmia with myocardial ischemia in hypertrophic cardiomyopathy--a case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12380941" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Atrial fibrillation precipitating sustained ventricular tachycardia in hypertrophic cardiomyopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25173338" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : 2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27166348" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Management of Atrial Fibrillation in Hypertrophic Cardiomyopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27912983" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Hypertrophic obstructive cardiomyopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24682347" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22068434" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : 2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33215931" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : 2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32860505" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9052657" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : The management of hypertrophic cardiomyopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29450893" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Dofetilide for suppression of atrial fibrillation in hypertrophic cardiomyopathy: A case series and literature review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16087104" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Complete pulmonary vein isolation guided by three-dimensional electroanatomical mapping for the treatment of paroxysmal atrial fibrillation in patients with hypertrophic obstructive cardiomyopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16500298" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Efficacy of catheter ablation of atrial fibrillation in patients with hypertrophic obstructive cardiomyopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17531584" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Usefulness and safety of transcatheter ablation of atrial fibrillation in patients with hypertrophic cardiomyopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25814420" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Outcomes of nonpharmacologic treatment of atrial fibrillation in patients with hypertrophic cardiomyopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24114776" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Catheter ablation of atrial fibrillation in hypertrophic cardiomyopathy: long-term outcomes and mechanisms of arrhythmia recurrence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26612881" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Outcomes of catheter ablation of atrial fibrillation in patients with hypertrophic cardiomyopathy: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27234160" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Catheter ablation for atrial fibrillation in hypertrophic cardiomyopathy: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31930545" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Five-year outcomes after catheter ablation for atrial fibrillation in patients with hypertrophic cardiomyopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14759397" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Effectiveness of atrial fibrillation surgery in patients with hypertrophic cardiomyopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14672530" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Combined cox maze procedure, septal myectomy, and mitral valve replacement for severe hypertrophic obstructive cardiomyopathy complicated by chronic atrial fibrillation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31727261" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Efficacy of Combined Cox-Maze IV and Ventricular Septal Myectomy for Treatment of Atrial Fibrillation in Patients With Obstructive Hypertrophic Cardiomyopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22354975" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Management of atrial fibrillation in patients with structural heart disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30503962" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Effect of hypertrophic cardiomyopathy on the prediction of thromboembolism in patients with nonvalvular atrial fibrillation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31340730" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Novel Oral Anticoagulants for Primary Stroke Prevention in Hypertrophic Cardiomyopathy Patients With Atrial Fibrillation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27339501" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Stroke and Bleeding Risks in NOAC- and Warfarin-Treated Patients With Hypertrophic Cardiomyopathy and Atrial Fibrillation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27060297" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : High Incidence of De Novo and Subclinical Atrial Fibrillation in Patients With Hypertrophic Cardiomyopathy and Cardiac Rhythm Management Device.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28247846" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Incidence of Device-Detected Atrial Fibrillation and Long-Term Outcomes in Patients With Hypertrophic Cardiomyopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28329139" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Duration of device-detected subclinical atrial fibrillation and occurrence of stroke in ASSERT.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7196768" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Arrhythmia in hypertrophic cardiomyopathy. I: Influence on prognosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7594081" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Hypertrophic cardiomyopathy in Tuscany: clinical course and outcome in an unselected regional population.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24965028" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Atrial fibrillation in hypertrophic cardiomyopathy: prevalence, clinical correlations, and mortality in a large high-risk population.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
